AI-assisted, human-published
08/27/2025 /Funding Events
Leal Therapeutics Raises $30M to Advance First-in-Class Therapeutics for CNS Disorders
Leal Therapeutics secures a $30 million Series A financing to progress novel therapeutics addressing metabolic imbalances in the brain for the treatment of CNS disorders, including schizophrenia and ALS.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com